Keratoacanthoma

• 

  Subject Areas on Research

  • Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. 
  • Keratoacanthoma of the bulbar conjunctiva.